First generic Qsymia reaches US pharmacies after June 2024 FDA approval

The FDA approved the first generic version of the weight-loss pill Qsymia on June 25, 2024, according to the approval letter for the application ^[2]. The generic version is sold as phentermine and topiramate extended-release (ER) capsules, and it did not reach U.S. pharmacies until May 7, 2025 ^[2].

Qsymia is an oral weight-loss medication approved for certain adults and adolescents ages 12 and older ^[2]. It is a pill rather than an injection, which puts it in a different category from the injectable GLP-1 drugs such as Ozempic, Wegovy and Mounjaro that have dominated recent weight-loss coverage ^[2].

Why approval did not mean immediate availability

The FDA treats "first generics" as important to public health and prioritizes its review of those applications, and it describes a first generic as the first approval that permits a manufacturer to market a generic version in the United States ^[1]. The agency also notes that approved drugs are not always available on or after the listed approval date and that patients should contact the company that holds the application for information about availability ^[1]. In this case, roughly 10 months passed between the June 2024 approval and the May 2025 launch ^[2].

The FDA has not said in these materials why the launch took that long, and no reason has been disclosed ^[1][2].

What the price difference looks like

Generic drugs are priced at a discount compared with their brand-name counterparts, and in many cases insurers prefer generics on their covered-drug lists ^[2]. GoodRx lists the generic as low as $59.05 at certain pharmacies with a coupon, and lists brand-name Qsymia at an exclusive cash price of $149.10 for a 30-day supply of the 7.5 mg/46 mg capsules ^[2]. GoodRx also reports that eligible patients may pay as little as $70 for brand-name Qsymia using a manufacturer copay card if their insurance covers the drug, and as little as $98 through the Qsymia Engage home-delivery program for people paying cash ^[2].

Those figures are cash prices listed by one discount program, and they are not the same as an insurance copay ^[2].

Why it matters for patients

The practical effect is that there is now a generic option for a non-injection weight-loss pill, which can matter for people whose insurance does not cover injectable GLP-1 drugs for weight loss ^[2]. Not all plans cover weight-loss medications, and coverage decisions sit with the individual plan ^[2]. A plan may also require prior authorization, which is an approval step before it will pay for a prescription ^[2].

Cost comparisons are not automatic. GoodRx notes that the brand-name product may sometimes be less expensive than the generic depending on a person's plan and whether they qualify for savings programs ^[2]. Pharmacies may also take time to stock the generic, so availability is not guaranteed the day a prescription is written ^[2].

Qsymia is approved for certain adults and adolescents age 12 and older; whether a generic is appropriate for a specific patient is a decision for that patient and their prescriber, and the sources here do not address switching between brand and generic in clinical terms ^[2].

What happens next

First generics are eligible for a six-month exclusivity period as the only generic version on the market, and after that period other generics may be released ^[2]. The FDA says more generics on the market boost competition, which can lower prices further ^[2]. That exclusivity period runs from the U.S. launch, which was May 7, 2025 ^[2]. It has not been reported how many additional manufacturers have applications pending, or what prices they would set.